Drug Profile
Acoltremon - Alcon
Alternative Names: AR-15512; AVX 012; WS-12Latest Information Update: 11 Jan 2024
Price :
$50
*
At a glance
- Originator Instituto de Neurociencias de Alicante
- Developer Alcon; AVX Pharma
- Class Cyclohexanes; Ethers; Eye disorder therapies; Small molecules
- Mechanism of Action TRPM8 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry eyes
Most Recent Events
- 10 Jan 2024 Topline pooled efficacy and adverse events data from the phase III COMET-2 and COMET-3 trials in Dry eyes released by Alcon
- 09 Jan 2024 Alcon announces intention to submit NDA to FDA for Dry eyes in mid-2024
- 17 Oct 2023 Aerie Pharmaceuticals completes the COMET-3 trial for Dry eyes in USA (Ophthalmic) (NCT05360966)